ARTICLE | Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

SUNY Downstate spinout takes aim at metastatic breast cancer by targeting p27

August 28, 2020 9:42 PM UTC

Concarlo is developing targeted therapies for metastatic breast cancer that take aim at both CDK4/6-driven cell proliferation and CDK2-driven drug resistance in one go. 

The company spun out of SUNY Downstate Medical Center, where Concarlo Holdings LLC co-founder and CEO Stacy Blain is an associate professor of pediatrics and cell biology...